Beyond monoamine-based therapies: Clues to new approaches

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 2, 2002, Pages 19-23

  Skolnick, Phil ^a  

^a DOV Pharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR AGONIST; ANTIDEPRESSANT AGENT; CITALOPRAM; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; GLUTAMATE RECEPTOR; LY 392098; MONOAMINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DEPRESSION; DRUG INDUCED DISEASE; DRUG RESEARCH; HUMAN; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; REMISSION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; CARRIER PROTEINS; DEPRESSIVE DISORDER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOWN-REGULATION; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RATS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROTRANSMITTER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS;

EID: 0036197522     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Antidepressants for the new millennium
2. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial
3. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: A microdialysis study
4. The novel 5-hydroxy-tryptamine(1A) antagonist LY426965: Effects on nicotine withdrawal and interactions with fluoxetine
5. Does the addition of pindolol accelerate the response to electroconvulsive therapy in patients with major depression? A double-blind, placebo-controlled pilot study
6. Pindolol augmentation of antidepressant treatment: Recent contributions from brain imaging studies
7. Current perspectives on the development of non-biogenic amine-based antidepressants
8. 1A receptors in vivo and in vitro: Implications for antidepressant therapy
9. Repeated imipramine treatment increases the responsivity of the rat hippocampus to dopamine: An in vitro study
10. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression
11. A molecular and cellular theory of depression
12. Neurotrophins and depression
13. Multiple promoters direct tissue-specific expression of the rat BDNF gene
14. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors
15. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator
16. Antidepressant-like actions of an AMPA receptor potentiator (LY392098)
17. Intra- and interstrain differences in models of "behavioral despair"
18. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
19. Antidepressant effects of ketamine in depressed patients
20. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain: A quantitative in situ hybridization study
21. Regulation of BDNF and trkB mRNA following chronic electroconvulsive seizure and antidepressant drug treatments
22. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus
23. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment
24. Brain-derived neurotrophic factor and basic fibroblast growth downregulate NMDA receptor function in cerebellar granule cells